Vaxart starts Ph1 oral vax trial

Tools

San Francisco-based Vaxart has started dosing patients in its first Phase I trial using its oral vaccine platform. The study uses an H5N1 flu vaccine, but the platform, if effective, could be used with several other vaccines. The trial will take place in the U.S. Vaxart release

Comments